Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NATRON: Benralizumab in Hypereosinophilic Syndrome
NCT04191304Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2020
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
A Phase 3 trial of benralizumab in hypereosinophilic syndrome (HES), sponsored by AstraZeneca. Started Jul 2020; status: active, not recruiting.
02
Drugs
benralizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT04191304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04191304.